ClinicalTrials.gg
TerminatedNCT01737879Updated Apr 21, 2014Results posted

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

A Phase 4 interventional study of Peginesatide and Epoetin alfa in Anemia, sponsored by Amgen. Terminated at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Why this study was terminated
Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted prematurely and will not resume; participants are no longer being treated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing peginesatide in Anemia — none open to participants now, none under way, none of them phase 3. peginesatide · Anemia.

Enrollment
16th of 20
41 · median 97
Started
2012
the only one that year
Phase 4
Only one
of the 20
Registered
19th of 20
by date
Lead sponsor
1 of 20
Amgen

Among the 20 studies testing peginesatide in Anemia, this one is the 16th largest by enrollment, is the only one that started in 2012, is the only one in phase 4, and was the 19th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 214 are open to participants now.

Browse Anemia studies →

Open to participants now

None of the 20 studies testing peginesatide in Anemia is open now. The open studies under Anemia, anywhere →

About peginesatide

peginesatide: first FDA approval 2012 (OMONTYS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Anemia studies recruiting now, 67 (55%) set no upper age limit and 36 (30%) stop at 75 or younger; 33 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing peginesatide in Anemia as a file.
02

Study summary

The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.

Read the detailed description

This is a phase 4, multicenter, single-arm, open-label study designed to evaluate whether patients receiving hemodialysis and treated with peginesatide can be converted to epoetin alfa using a predefined conversion table while achieving stable hemoglobin. The study will be conducted in two phases. Hemodialysis patients treated with epoetin alfa 3 times a week (TIW) will first be converted to peginesatide administered every 4 weeks (Q4W). After 24 weeks, these participants will be converted back to epoetin alfa administered TIW for 32 weeks. The primary endpoint will be the mean hemoglobin during the last 8 weeks of the epoetin alfa period.

03

Conditions studied

  • Anemia

Keywords

  • Anemia, Chronic Kidney Disease, End Stage Renal Disease, erythropoiesis-stimulating agents, Hemodialysis, Hemoglobin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving hemodialysis 3 times a week
  • Receiving epoetin alfa IV 3 times a week
  • concentration ≥ 9.0 and ≤ 12.0 g/dL within 8 weeks of or during screening

Key Exclusion Criteria:

  • Systemic hematologic disease
  • Changes in Epoetin alfa dose by ≥ 50% within 8 weeks of or during screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Peginesatide / Epoetin Alfa

    Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.

    Drug: Peginesatide · Drug: Epoetin alfa

Interventions

  • All participants will receive peginesatide for the first 24 weeks.

    Also known as: Omontys

  • All participants converted to epoetin alfa at week 25 for a total of 32 weeks

    Also known as: Epogen

06

What researchers measure

Primary outcomes

  1. Mean Hemoglobin Concentration During the Evaluation Period

    The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants. No participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.

    Time frame: Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).

Secondary outcomes

  1. Mean Dose of Epoetin Alfa During the Evaluation Period

    No participant reached the evaluation period, therefore, this endpoint could not be evaluated.

    Time frame: Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).

  2. Hemoglobin Concentration by Visit

    Time frame: Baseline and Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21

  3. Peginesatide Dose by Visit

    Time frame: Baseline and Weeks 5, 9, 13, and 17

07

Results

Posted Apr 21, 2014

Participant flow

First patient was enrolled on 24 October 2012; Last patient was enrolled on 21 February 2013. The study was terminated on 27 March 2013.

Participant flow — Overall Study
MilestonePeginesatide
Started41
Received peginesatide34
Transitioned to epoetin alfa0
Completed0
Not completed41
Withdrew: Death1
Withdrew: Sponsor decision40

Outcome measures

PrimaryMean Hemoglobin Concentration During the Evaluation Period

The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants. No participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.

Time frame:
Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).

No measurements were reported for this outcome.

SecondaryMean Dose of Epoetin Alfa During the Evaluation Period

No participant reached the evaluation period, therefore, this endpoint could not be evaluated.

Time frame:
Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).

No measurements were reported for this outcome.

SecondaryHemoglobin Concentration by Visit
Time frame:
Baseline and Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21
Reported as:
Mean · g/dL
Hemoglobin Concentration by Visit
g/dLPeginesatide
Baseline (n=34)10.51 ± 0.76
Week 3 (n=34)11.09 ± 0.81
Week 5 (n=29)10.86 ± 0.87
Week 7 (n=21)11.03 ± 1.02
Week 9 (n=20)10.59 ± 0.84
Week 11 (n=19)10.80 ± 0.97
Week 13 (n=14)10.50 ± 0.94
Week 15 (n=10)10.70 ± 0.82
Week 17 (n=10)10.35 ± 1.31
Week 19 (n=10)10.93 ± 0.94
Week 21 (n=1)10.10 ± NA
End of study visit (n=32)10.55 ± 0.63
SecondaryPeginesatide Dose by Visit
Time frame:
Baseline and Weeks 5, 9, 13, and 17
Reported as:
Mean · mg
Peginesatide Dose by Visit
mgPeginesatide
Baseline (n=30)5.42 ± 2.48
Week 5 (n=16)5.04 ± 1.32
Week 9 (n=15)4.98 ± 2.00
Week 13 (n=9)4.00 ± 2.53
Week 17 (n=9)5.12 ± 3.29

Adverse events

Collected over From informed consent up to 30 days post treatment, or end of study. Maximum time on study was 6 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginesatide—3/34 (8.8%)6/34 (17.6%)
Most frequent serious events
Most frequent serious events
EventPeginesatide
Ventricular asystoleCardiac disorders1/34
Small intestinal obstructionGastrointestinal disorders1/34
CholelithiasisHepatobiliary disorders1/34
GastroenteritisInfections and infestations1/34
PneumoniaInfections and infestations1/34
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/34
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/34
Most frequent other events
Most frequent other events
EventPeginesatide
OedemaGeneral disorders2/34
HeadacheNervous system disorders2/34
HypertensionVascular disorders2/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Peginesatide
Mean63.2 ± 16.6
Sex: Female, Male
Sex: Female, Male(Participants)Peginesatide
Female21
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Peginesatide
Black or African American24
White16
Other1
08

Study locations

23 sites
  • Research Site
    Phoenix, Arizona 85004, United States
  • Research Site
    Tempe, Arizona 85284, United States
  • Research Site
    Azusa, California 91702, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    Paramount, California 90723, United States
  • Research Site
    Riverside, California 92501, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Orange, Connecticut 06477, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Bayonne, New Jersey 07002, United States
  • Research Site
    Amherst, New York 14221, United States
  • Research Site
    Yonkers, New York 10704, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Orangeburg, South Carolina 29118, United States
  • Research Site
    Dyersburg, Tennessee 38024, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Mar 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2012
First posted
Nov 30, 2012
Start
Oct 2012
Primary completionActual
Mar 2013
CompletionActual
Jul 2013
Results first posted
Apr 21, 2014
Last update
Apr 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01737879
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Oct 2012
Primary completion
Mar 2013
Completion
Jul 2013
Results posted
Apr 21, 2014
Last update
Apr 21, 2014

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginesatide · Epoetin Alfa

Start the discussion